atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
Helping medical device companies navigate quality, compliance and regulatory pathways with confidence
Bringing a medical device to market requires more than innovative technology. Successful commercialisation depends on robust quality systems, effective risk management and a clear understanding of complex regulatory…
Discover Canada’s healthcare technology leaders connecting with the UK health and life sciences ecosystem
Healthcare innovation is increasingly shaped by international collaboration. By bringing together expertise from different markets, healthcare systems can accelerate the development, validation and adoption of technologies…